Skip to main content
Erschienen in: World Journal of Urology 12/2018

01.08.2018 | Topic Paper

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

verfasst von: Lorenzo Marconi, Roderick de Bruijn, Erik van Werkhoven, Christian Beisland, Kate Fife, Axel Heidenreich, Anil Kapoor, Jose Karam, Caroline Kauffmann, Tobias Klatte, Boerje Ljungberg, Surena Matin, Daniel Sjoberg, Michael Staehler, Grant D. Stewart, Simon Tanguay, Robert Uzzo, Sarah Welsh, Lori Wood, Chris Wood, Axel Bex

Erschienen in: World Journal of Urology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Recent trials have emphasized the importance of a precise patient selection for cytoreductive nephrectomy (CN). In 2013, a nomogram was developed for pre- and postoperative prediction of the probability of death (PoD) after CN in patients with metastatic renal cell carcinoma. To date, the single-institutional nomogram which included mostly patients from the cytokine era has not been externally validated. Our objective is to validate the predictive model in contemporary patients in the targeted therapy era.

Methods

Multi-institutional European and North American data from patients who underwent CN between 2006 and 2013 were used for external validation. Variables evaluated included preoperative serum albumin and lactate dehydrogenase levels, intraoperative blood transfusions (yes/no) and postoperative pathologic stage (primary tumour and nodes). In addition, patient characteristics and MSKCC risk factors were collected. Using the original calibration indices and quantiles of the distribution of predictions, Kaplan–Meier estimates and calibration plots of observed versus predicted PoD were calculated. For the preoperative model a decision curve analysis (DCA) was performed.

Results

Of 1108 patients [median OS of 27 months (95% CI 24.6–29.4)], 536 and 469 patients had full data for the validation of the pre- and postoperative models, respectively. The AUC for the pre- and postoperative model was 0.68 (95% CI 0.62–0.74) and 0.73 (95% CI 0.68–0.78), respectively. In the DCA the preoperative model performs well within threshold survival probabilities of 20–50%. Most important limitation was the retrospective collection of this external validation dataset.

Conclusions

In this external validation, the pre- and postoperative nomograms predicting PoD following CN were well calibrated. Although performance of the preoperative nomogram was lower than in the internal validation, it retains the ability to predict early death after CN.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed
2.
3.
Zurück zum Zitat Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J et al (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48:231–238CrossRefPubMed Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J et al (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48:231–238CrossRefPubMed
4.
Zurück zum Zitat Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924CrossRefPubMed Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924CrossRefPubMed
5.
Zurück zum Zitat Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659CrossRefPubMed Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659CrossRefPubMed
6.
Zurück zum Zitat Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMed Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMed
7.
Zurück zum Zitat Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076CrossRefPubMed Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076CrossRefPubMed
8.
Zurück zum Zitat Bex A, Ljungberg B, van Poppel H, Powles T, European Association of U (2016) The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 70:901–905CrossRefPubMed Bex A, Ljungberg B, van Poppel H, Powles T, European Association of U (2016) The role of cytoreductive nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 70:901–905CrossRefPubMed
9.
Zurück zum Zitat Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S et al (2010) Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 58:819–828CrossRefPubMed Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S et al (2010) Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol 58:819–828CrossRefPubMed
11.
Zurück zum Zitat Bex A, Mulders P, Jewett M, Wagstaff J, van Velthoven R, Laguna Pes P et al (2017) LBA35Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann Oncol 28:v605–v649CrossRef Bex A, Mulders P, Jewett M, Wagstaff J, van Velthoven R, Laguna Pes P et al (2017) LBA35Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann Oncol 28:v605–v649CrossRef
12.
Zurück zum Zitat Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Mejean A et al (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol 71:845–847CrossRefPubMed Stewart GD, Aitchison M, Bex A, Larkin J, Lawless C, Mejean A et al (2017) Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol 71:845–847CrossRefPubMed
13.
Zurück zum Zitat Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY et al (2010) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 106:218–223CrossRefPubMed Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY et al (2010) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 106:218–223CrossRefPubMed
14.
Zurück zum Zitat Bex A, Powles T (2012) Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev Anticancer Ther 12:787–797CrossRefPubMed Bex A, Powles T (2012) Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev Anticancer Ther 12:787–797CrossRefPubMed
15.
Zurück zum Zitat Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158:1691–1695CrossRefPubMed Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158:1691–1695CrossRefPubMed
16.
Zurück zum Zitat Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF et al (2010) Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116:3378–3388CrossRefPubMed Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF et al (2010) Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116:3378–3388CrossRefPubMed
17.
Zurück zum Zitat Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM et al (2013) Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63:947–952CrossRefPubMed Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM et al (2013) Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63:947–952CrossRefPubMed
18.
Zurück zum Zitat Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15:e549–e561CrossRefPubMed Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15:e549–e561CrossRefPubMed
19.
Zurück zum Zitat Altman DG, Vergouwe Y, Royston P, Moons KG (2009) Prognosis and prognostic research: validating a prognostic model. BMJ 338:b605CrossRefPubMed Altman DG, Vergouwe Y, Royston P, Moons KG (2009) Prognosis and prognostic research: validating a prognostic model. BMJ 338:b605CrossRefPubMed
20.
Zurück zum Zitat Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337–344CrossRefPubMed Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337–344CrossRefPubMed
21.
Zurück zum Zitat Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak 26:565–574CrossRef Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak 26:565–574CrossRef
22.
Zurück zum Zitat Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M et al (2017) The difficulty in selecting patients for cytoreductive nephrectomy: an evaluation of previously described predictive models. Urol Oncol 35(35):e1–e5 Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M et al (2017) The difficulty in selecting patients for cytoreductive nephrectomy: an evaluation of previously described predictive models. Urol Oncol 35(35):e1–e5
24.
Zurück zum Zitat Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S et al (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60:644–661CrossRefPubMed Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S et al (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60:644–661CrossRefPubMed
25.
Zurück zum Zitat Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148CrossRefPubMedPubMedCentral Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN et al (2013) External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540CrossRefPubMed Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540CrossRefPubMed
27.
Zurück zum Zitat Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRefPubMed Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799CrossRefPubMed
28.
Zurück zum Zitat Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66:704–710CrossRefPubMed Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66:704–710CrossRefPubMed
29.
Zurück zum Zitat Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550CrossRefPubMed Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550CrossRefPubMed
30.
Zurück zum Zitat Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 13:1460–1468CrossRefPubMed Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C et al (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 13:1460–1468CrossRefPubMed
31.
Zurück zum Zitat Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S et al (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17:5443–5450CrossRefPubMedPubMedCentral Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S et al (2011) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 17:5443–5450CrossRefPubMedPubMedCentral
Metadaten
Titel
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
verfasst von
Lorenzo Marconi
Roderick de Bruijn
Erik van Werkhoven
Christian Beisland
Kate Fife
Axel Heidenreich
Anil Kapoor
Jose Karam
Caroline Kauffmann
Tobias Klatte
Boerje Ljungberg
Surena Matin
Daniel Sjoberg
Michael Staehler
Grant D. Stewart
Simon Tanguay
Robert Uzzo
Sarah Welsh
Lori Wood
Chris Wood
Axel Bex
Publikationsdatum
01.08.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2427-z

Weitere Artikel der Ausgabe 12/2018

World Journal of Urology 12/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.